Regulated information

Universal registration document 2023 XBRL version

Universal Registration Document including the Annual Financial Report

Universal registration document 2023

Universal Registration Document including the Annual Financial Report

ANNUAL RESULTS 2023 (slideshow)

01.2023 Highlights
02.2023 Consolidated financial statements
03.Strategy and outlook

Universal registration document 2022

Universal Registration Document including the Annual Financial Report

Document d’enregistrement universel (URD) 2022 version XBRL

Document d'enregistrement universel 2022 incluant le rapport financier annuel

[VIDEO] Présentation des résultats annuels 2022 -French

Présentation analystes & investisseurs - 23 Mars 2023

ANNUAL RESULTS 2022 (slideshow)

01.2022 Highlights
02.2022 Consolidated financial statements
03.Strategy and outlook

Universal registration document 2021

Universal Registration Document including the Annual Financial Report

Annual results 2021 (slideshow)

This document was prepared by Vetoquinol for the sole purpose of presenting the annual results for the year 2021 on March 24, 2022.

[AUDIO] Présentation des résultats 2021

Présentation analystes & investisseurs - 24 mars 2022

2020 Universal registration document

2020 universal registration document including the Annual Financial Report

[VIDEO ]Présentation des résultats 2020 - french

Présentation analystes & investisseurs - 1er avril 2021

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

2019 Universal registration document

[AUDIO] Présentation des résultats 2019

Présentation analystes & investisseurs - 26 mars 2020

2019 annual results

2018 registration document

2018 Annual results

2017 Registration document

2017 Registration document

[AUDIO] Présentation des résultats 2017

Présentation analystes & investisseurs - 15 mars 2018

2017 Results

Investors and Analysts - March 15, 2018

2016 Registration document

Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2016. The original French document was filed with the AMF (French Financial Markets Authority) on April 26, 2017.

Présentation des résultats 2016 - french

Vétoquinol - 23.03.2017 - 18h15 - Enregistrement Audio Conference

2016 Annual Results

Présentation analystes & investisseurs - 23 mars 2017

2015 Registration document

Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2015. The original French document was filed with the AMF (French Financial Markets Authority) on April 26, 2016.

2015 Annual Results

2015 Annual Results

Registration Document 2014

Registration Document 2014

2014 annual results

Sustained growth, Reference products drive growth in 2014.
<br />
2014 key figures.

Reference Document 2013

Reference Document 2013

2013 annual results

SFAF meeting March 13, 2014

Vétoquinol : 80 years striving for animal health worldwide

Founded in 1933, Vétoquinol is now a leading global animal health company.
The number 10 global animal health company and the third
largest in France, the Vétoquinol Group combines sustainability,
growth and independence in an increasingly competitive world
market.
Committed to the protection and well-being of both animals
and people, Vétoquinol creates, develops and sells veterinary
drugs and non-medical products all over the world.
The company is widely reputed for its expertise in the fields of infectious diseases, pain and inflammation in livestock (cattle and pigs) and pets (dogs and cats).
For over 80 years, Vétoquinol's pursuit of growth has been underpinned by strong values of team spirit, performance and the sharing of corporate culture and know-how with customers, vets, breeders, partners and employees alike.

Financial statements 2012

1.1CONSOLIDATED FINANCIAL STATEMENTS p.4

Reference Document 2012 (in french)

Reference Document 2012 (in french)

2012 ANNUAL RESULTS

SFAF Meeting March 27, 2013

Reference document 2011

Reference document 2011

2011 ACTIVITY REPORT

Our business: animals. Our advantage: people.

2011 ANNUAL RESULTS

SFAF meeting April 4, 2012

2010 Activity Report

P_06 VÉTOQUINOL’S PROUD HISTORY
<br>
P_12 SPOTLIGHT ON INNOVATION
<br>
P_18 AN ONGOING DAILY COMMITMENT
TO VETERINARIANS
<br>
P_24 AN INTERNATIONAL COMPANY
MAINTAINING A LOCAL PRESENCE
IN GLOBAL MARKETS
<br>
P_28 GOVERNANCE AND KEY FIGURES

Reference document 2010

Reference document 2010

2010 annual earnings Vétoquinol

Contents :
<br>> Highlights
<br>> 2010 Consolidated
Financial Statements
<br>> Strategy and Outlook
<br>> Questions and Answers

Reference Document 2009

Reference Document 2009

2009 activity report

2009 Annual earnings

2009 Annual earnings

Rapport financier semestriel 2009 (french)

Le chiffre d’affaires de Vétoquinol pour le 1er semestre 2009 s’établit à 119,9 M€, en croissance de 2,7% par rapport au premier semestre de l’exercice précédent.

Vétoquinol: H1 2009 interim earnings

2008 activity report

2008 financial report

Laboratoire pharmaceutique vétérinaire familial et indépendant, Vétoquinol se consacre exclusivement à la santé animale. Son activité est volontairement équilibrée entre animaux de rente et animaux de compagnie.
<br>
Historiquement implanté sur le marché français, le groupe réalise désormais 78% de son chiffre d'affaires consolidé à l'international (234,4 millions d'euros en 2008). Les 1400 collaborateurs du Groupe se répartissent entre la Recherche & Développement, la production et la commercilisation.
<br>
Aujourd'hui, la PME française -11e acteur mondial en santé animale (hors aliments)- produit et distribue 700 médicaments et produits non médicamenteux dans près de 100 pays (Europe, Amérique du Nord et Asie). Elle s'appuie sur ses filiales dans 22 pays et sur un réseau de 140 partenaires distributeurs.

2008 Annual earnings

Operating highlights
- Key figures
- Revenues
- External growth
- A strategy of product innovation

Rapport semestriel Vétoquinol 2008 (french)

Vétoquinol a réalisé de bons résultats au premier semestre 2008 : le chiffre d’affaires
progresse de 5,0% et le résultat net après impôts de 15,3%.

Vétoquinol: H1 2008 interim earnings

Activity Report 2007

Financial report 2007

Consolidated 2007 figures are even better than the targets in the business plan we presented for the initial public offering (IPO) in November 2006.
<br>
Revenues rose by 10.3% to 233.4 million euros (211.6 million euros in 2006), including 7.6% organic growth.
<br>
The operating profit from continuing operations increased by 13.9%, from 25.6 million euros in 2006 to 29.2 million euros in 2007.
<br>
Finally, net profit increased by 17.8% to 18.6 million euros in 2007 (15.8 million euros in 2006), for a net margin of 8% (7.5% the previous year).

2007 annual earnings Vétoquinol

Etats financiers consolidés au 31 décembre 2006 (french)